EXHIBIT 1

EXHIBIT 1

PLAINTIFFS' STATEMENT OF FACTS REMAINING TO BE LITIGATED

A. The '098 Patent

1. The parties contest whether claim 10 of the '098 patent was obvious over the prior art available prior to August 16, 1984. In particular, Teva contends that claim 10 of the '098 patent was obvious in view of omeprazole.

2. Plaintiffs will show that Teva cannot prove that claim 10 of the '098 patent was obvious, and there is certainly not clear and convincing evidence of obviousness as required by law. It is undisputed that lansoprazole was a new compound in August 1984. It is undisputed that lansoprazole had not been described prior to August 1984. It is undisputed that lansoprazole is a useful pharmaceutical. Lansoprazole is one of only five known safe and effective proton-pump inhibitors ("PPIs"). Plaintiffs will show that one of skill in the art of PPIs in August, 1984 would not have found lansoprazole obvious in light of the prior art. There was no reason in August, 1984 for a person of ordinary skill to modify omeprazole, or any other prior art compound, to make lansoprazole. Moreover, the art was highly unpredictable and the critical aspects of the complex chemistry of PPIs were not known in August, 1984. One of ordinary skill in the art could not predict what choice of chemical substitutions would lead to a successful PPI that was active, stable and had few side effects.

3. The parties contest whether there is evidence of secondary considerations of non-obviousness of claim 10 of the '098 patent. Plaintiffs will show that secondary considerations of commercial success, failure of others, copying, initial skepticism and unexpected results further demonstrate that lansoprazole was not obvious.

4. The parties contest whether the '098 patent was procured by inequitable conduct. In particular, Teva contends that Takeda intentionally withheld additional experimental

results that are allegedly inconsistent with the results of experiments using the IMAU model presented in Table 1 of the '098 patent (Col. 6, ll. 5-28). Plaintiffs will show that the models used in those experiments are not comparable to the IMAU model disclosed in the '098 patent and are in any event not inconsistent or material to the results presented in the '098 patent. Plaintiffs will additionally show that there is no evidence that any individual at Takeda involved in the prosecution of the '098 patent intended to deceive the Patent Office.

B. The '321 Patent

5. The parties contest whether claim 2 of the '321 patent is infringed either literally or under the doctrine of equivalents by the products described in Teva's ANDA No. 77-255. In particular, Plaintiffs will show that the formulation of Teva's product meets each and every limitation of claim 2 of the '321 patent as properly construed.

6. The parties contest whether claim 2 of the '321 patent was obvious over the prior art available as of February 13, 1986. Plaintiffs will show that the invention claimed in claim 2 of the '321 patent would not have been obvious to a person or ordinary skill in the art in February, 1986. Prior to the invention of the '321 patent, there was no teaching or suggestion in the art that lansoprazole could be stabilized in a solid-state phase and *in vivo* using a basic organic salt and a coating agent. Plaintiffs will show that the prior art cited by Teva's experts does not teach or suggest the invention of claim 2 of the '321 patent, nor does the general knowledge within the art in February, 1986.

C. Injunction

7. The parties contest whether Plaintiffs will be irreparably harmed absent the grant of an injunction by the Court preventing Teva from marketing its proposed lansoprazole delayed release capsule products described in ANDA No. 77-255 before the expiration of the '098 and '321 patents. Plaintiffs will show that they will be irreparably harmed

by Teva's entry into the market and that Plaintiff will suffer damages in excess of Teva's resources to pay.

EXHIBIT 2

EXHIBIT 2

DEFENDANTS' STATEMENT OF FACTS REMAINING TO BE LITIGATED

A. The '098 Patent

1. Teva will prove by clear and convincing evidence that claim 10 of the '098 patent was anticipated under section 102 of the Patent Code or obvious under section 103 of the Patent Code as of August 16, 1984, the date on which the priority application was filed. Claim 10 claims the molecular structure for the compound lansoprazole. Lansoprazole is one of a class of anti-ulcer drugs known as proton proton-pump inhibitors ("PPIs").

2. Claim 10 of the '098 patent is anticipated or rendered obvious by, at least, the following prior art: (1) PPI compounds developed and patented by Hässle, including omeprazole (the first commercially available PPI); (2) PPI compounds developed and patented by Byk Gulden; and (3) an article authored by George Sachs. These references establish that, as of August 1984, the benzimidazole-methylsulfinyl-pyridine backbone structure common to PPI compounds (and first used in the PPI timoprazole in the 1970s) was known, it was known to use an alkoxy compound at the R4 position of the pyridine ring of the backbone structure, it was known to use fluorinated substituents in PPIs, and having a pKa value of the pyridine ring of approximately 4.0 allowed the PPI to avoid premature activation in slightly acidic portions of the body and to accumulate in the parietal cell where the PPI can properly activate.

3. Teva also will demonstrate that its prima facie case of obviousness of the '098 patent is not rebutted by any alleged secondary considerations of non-obviousness. First, Teva will show that Plaintiffs cannot establish unexpectedly superior potency of lansoprazole over prior art products. Plaintiffs were in possession of data that demonstrated that lansoprazole was not unexpectedly superior in potency to omeprazole or a specific Byk Gulden compound. Further, Teva has conducted its own experiments using the same animal model disclosed in the

'098 patent that show lansoprazole and prior art compounds to be of the same order of magnitude in potency.

4. Second, Teva will show that there is no demonstrable connection between properties of the lansoprazole compound (or its formulation) and sales of TAP's Prevacid product sufficient to establish any alleged commercial success. Rather, such sales are due to the pre-existing PPI market established by omeprazole and advertising efforts by TAP after Prevacid was launched.

5. Third, Teva will show that Plaintiffs cannot prove that others in the industry were initially skeptical of PPI compounds or that others in the industry failed to develop their own PPIs. In addition, Teva will demonstrate that its use of the active ingredient lansoprazole is required by statute and does not constitute a decision to "copy" any alleged invention of the '098 patent. Indeed, as required by statute, Teva has used the active ingredient in each of the commercially available PPIs in seeking approval from the U.S. Food and Drug Administration ("FDA") to market generic versions of those products.

6. Teva will prove by clear and convincing evidence that the '098 patent was procured by inequitable conduct. In support of the patentability of the '098 patent, Takeda introduced experimental data from an indomethacin-induced antral ulcer rat model ("IMAU model") purporting to show that lansoprazole was superior in potency to prior art compounds, including omeprazole and a specific Byk Gulden compound. (See '098 patent, col. 6, ll. 5-28.) Teva will prove that Takeda was in possession of and intentionally withheld from the U.S. Patent and Trademark Office ("PTO") experimental results from the IMAU model and other relevant testing models that are inconsistent with the data submitted to the PTO. This includes data submitted to the FDA in the application seeking approval for the sale of lansoprazole in the U.S.

Teva also will show that data from models other than the IMAU model are just as relevant to the potency of a PPI as the data actually submitted and would have been considered highly material to the prosecution of the application by a reasonable Patent Examiner. Teva further will show that, given Takeda's undisputed knowledge of the inconsistent experimental results and Takeda's decision to withhold such highly material information, it is proper to infer that Takeda had an intent to deceive the PTO.

B. The '321 Patent

7. Teva will prove by a preponderance of the evidence that claim 2 of the '321 patent is not infringed, either literally or under the doctrine of equivalents, by the products described in Teva's ANDA No. 77-255. In particular, Teva will show that Teva's products do not contain the "pharmaceutical composition" required by claim 2 of the '321 patent. Teva further will show that the benzimidazole compound (lansoprazole) and the basic inorganic salt (magnesium carbonate) in Teva's products are not "in contact … evenly" as required by the language of claim 2 of the '321 patent. Teva's non-infringement of claim 2 is demonstrated by the design specifications for Teva's proposed products set forth in its ANDA and testing performed on Teva's proposed products.

8. Teva also will prove by clear and convincing evidence that claim 2 of the '321 patent was obvious under section 103 of the Patent Code as of February 13, 1986, the date on which the priority application was filed. Teva will show that lansoprazole was a publicly known compound as of that date, that lansoprazole was known to be unstable in acidic environments, and that it was known to mix basic inorganic salts of magnesium with compounds that were unstable in acidic environments.

C. Injunction

9. Teva will demonstrate that an injunction by the Court preventing Teva from marketing the proposed lansoprazole delayed-release capsule products described in ANDA No. 77-255 before the expiration of the '098 and ’321 patents is not warranted. First, an injunction is not warranted because Teva has not infringed valid and enforceable patents, as explained above. Second, Plaintiffs will not be able to establish the factors for a permanent injunction discussed in eBay v. MercExchange, L.L.C., 126 S. Ct. 1837 (2006). Third, Teva will show that any damages incurred due to sales of Teva’s proposed products are calculable and would not exceed Teva’s ability to pay them.

10. Teva will demonstrate that this is an exceptional case under 35 U.S.C. § 285, and Teva should be awarded attorneys’ fees.

EXHIBIT 3

EXHIBIT 3

PLAINTIFFS' STATEMENT OF ISSUES OF LAW REMAINING TO BE LITIGATED

A. The '098 Patent

1. Whether the invention of claim 10 of the '098 patent is invalid over the prior art as obvious under § 103. 35 U.S.C. §282; 35 U.S.C. §103; Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).

2. Whether the invention of claim 10 of the '098 patent is unenforceable due to a violation of the duty to disclose in 37 C.F.R. § 1.56 during the prosecution of the '098 patent. Kingsdown Medical Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867 (Fed. Cir. 1988).

B. The '321 Patent

3. Whether Teva literally infringes claim 2 of the '321 patent, under a proper claim construction, or induces infringement of claim 2 of the '321 patent through Teva's submission of ANDA No. 77-255 to the FDA. 35 U.S.C. § 271(e)(2).

4. Whether Teva infringes claim 2 of the '321 patent under the doctrine of equivalents through Teva's submission of ANDA No. 77-255 to the FDA. 35 U.S.C. § 271(e)(2). Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997).

5. Whether the invention of claim 2 of the '321 patent is invalid over the prior art as obvious under § 103. 35 U.S.C. §282; 35 U.S.C. §103; Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).

C. Injunction

6. Whether Plaintiffs are entitled to a permanent injunction enjoining Teva USA and Teva Industries, their officers, agents, attorneys and employees, and those acting in privity or concert with them, from engaging in the commercial manufacture use, offer for sale, or sale within the United States, or importation into the United States, of the lansoprazole delayed

release capsule products described in ANDA No. 77-255 until the date of the last to expire of any patent in suit is found valid and infringed by Teva. 35 U.S.C. § 271(e)(4)(A).

7. Whether this is an exceptional case under 35 U.S.C. § 285.

EXHIBIT 4

EXHIBIT 4

DEFENDANTS' STATEMENT OF ISSUES OF LAW REMAINING TO BE LITIGATED

A. The '098 Patent

1. Whether claim 10 of the '098 patent is invalid as anticipated under 35 U.S.C. § 102 or obvious under 35 U.S.C. § 103. 35 U.S.C. § 282; 35 U.S.C. § 102; 35 U.S.C. § 103; Graham v. John Deere Co., 383 U.S. 1 (1966).

2. Whether claim 10 of the '098 patent is unenforceable due to a violation of the duty to disclose in 37 C.F.R. § 1.56 during the prosecution of the '098 patent. Kingsdown Medical Consultants, Ltd. v. Hollister, Inc., 863 F.2d 867 (Fed. Cir. 1988).

3. Teva continues to believe that the Court should hear the issue of whether claim 10 of the '098 patent is unenforceable due to a violation of the duty to disclose in connection with the patent term extension. Teva respectfully disagrees with the Court's July 3, 2007 ruling preventing Teva from litigating this issue and hereby preserves the patent term extension issue for any appeal.

B. The '321 Patent

4. The proper construction of claim terms in claim 1 of the '321 patent, upon which asserted claim 2 depends. Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005).

5. Whether Teva's submission of ANDA No. 77-255 to the FDA constitutes literal infringement of or inducement of infringement of claim 2 of the '321 patent, as construed by the Court. 35 U.S.C. § 271(e)(2).

6. Whether Teva's submission of ANDA No. 77-255 to the FDA constitutes infringement under the doctrine of equivalents of claim 2 of the '321 patent, as construed by the Court. 35 U.S.C. § 271(e)(2); Warner-Jenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17 (1997).

7. Whether claim 2 of the '321 patent is invalid as obvious under 35 U.S.C. § 103. 35 U.S.C. § 282; 35 U.S.C. § 103; Graham v. John Deere Co., 383 U.S. 1 (1966).

C. Injunction

8. If Plaintiffs prove that Teva infringes a valid and enforceable claim of either the '098 or '321 patent, whether Plaintiffs then can prove that they are entitled to a permanent injunction enjoining Teva from manufacturing, using, offering for sale, or selling within the United States, or importing into the United States, the lansoprazole delayed-release capsule products described in ANDA No. 77-255 until the date of the last to expire of the patents that Teva is found to have infringed. 35 U.S.C. § 271(e)(4)(A); eBay v. MercExchange, 126 S.Ct. 1837 (2006).

7. Whether the prevailing party is entitled to a ruling that this is an exceptional case under 35 U.S.C. § 285.

EXHIBIT 5

Takeda Pharmaceutical, Inc.. and TAP
v.
Teva Pharmaceuticals Case Number: 06:0033-SLR

Exhibit 5
Plaintiffs' Trial Exhibit List

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0001						U.S. Patent 4,628,098	
PTX0002						098 File history	
PTX0003						U.S. Patent 5,045,321	
PTX0004						321 File history	
PTX0005	Lipinski Expert Report 1				6/18/2007	Lipinski CV	LIPINSKI 000001-000027
PTX0006	Lipinski Expert Report 2				12/9/1986	U.S. Patent 4,628,098	LIPINSKI 000028-000038
PTX0007	Lipinski Expert Report 3				6/13/2006	Amended Complaint with exhibits (C.A. No. 06-033)	LIPINSKI 0039-0120
PTX0008	Lipinski Expert Report 4				6/29/2006	Teva Pharmaceuticals USA and Teva Pharmaceutical Industries Answer, Defenses, and Counterclaims to Amended Complaint	LIPINSKI 0121-0141
PTX0009	Lipinski Expert Report 5				1/18/2007	Teva Pharmaceuticals USA and Teva Pharmaceutical Industries Responses and Objections to Takeda's First Set of Requests for Admissions No. 1-3	LIPINSKI 0142-0146
PTX0010	Lipinski Expert Report 6					Form FDA 356h from Teva's ANDA produced at TVL 001	LIPINSKI 0147
PTX0011	Lipinski Expert Report 7					Section IV: Comparisons produced at TVL 022-024	LIPINSKI 0148-0150
PTX0012	Lipinski Expert Report 8					Section V: Labeling produced at TVL 025-054	LIPINSKI 0151-0180
PTX0013	Lipinski Expert Report 9					Labeling Amendment produced at TVL 62503-62539	LIPINSKI 0181-0217
PTX0014	Lipinski Expert Report 10				12/5/2005	Paragraph IV Certification Notice Letter produced at TVL 28243-28254	LIPINSKI 0218-0229
PTX0015	Lipinski Second Expert Report 2				1978	Cimetidine: A review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease *Drugs*, vol.15, no. 2, p. 93-131 (1978)	LIPINSKI 000648-000686
PTX0016	Lipinski Second Expert Report 3				2006	The Chemically elegant proton pump inhibitors *Am. J. Pharm. Educ.*, vol. 70(5), Article 101, pp. 1-11 (2006)	LIPINSKI 000893-000903
PTX0017	Lipinski Second Expert Report 4					Chemistry of covalent inhibition of the gastric (h, k)-ATPhase by proton pump inhibitors *J. Am. Chem. Soc.*, vol. 126, pp. 7800-7811 (2004)	LIPINSKI 000960-000971
PTX0018	Lipinski Second Expert Report 5				1995	Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole *Aliment Pharmacol. Ther., vol. 9, pp. 363-378 (1995)*	LIPINSKI 000726-000741
PTX0019	Lipinski Second Expert Report 6				1985	Structure activity relationships of substituted benzimidazoles *Scand. J. Gastroenterol., vol. 20(suppl. 108), pp. 15-22 (1985)*	LIPINSKI 000640-000647

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 17 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0020	Lipinski Second Expert Report 7				1989	*Acta Cryst*., vol. C45, pp. 1921-1923 (1989)	LIPINSKI 000843-000845
PTX0021	Lipinski Second Expert Report 8				2003	*Ann. N.Y. Acad. Sci*., vol. 986, pp.106-110 (2003)	LIPINSKI 000838-000842
PTX0022	Lipinski Second Expert Report 9				1983	*Gastroenterology*, vol. 85, pp. 900,-907 (1983)	LIPINSKI 000772-000779
PTX0023	Lipinski Second Expert Report 10				1983	*J. of Chromatography*, vol. 278, pp. 311-319 (1983)	LIPINSKI 000829-000837
PTX0024	Lipinski Second Expert Report 11				1984	The New England Journal of Medicine: Pump Blockers and Ulcer Disease New Engld. J. Med., vol. 310, no. 12, pp. 785-786 (1984)	LIPINSKI 000904-000905
PTX0025	Lipinski Second Expert Report 12				1986	*J. Chem. Soc., Chem. Commun.*, pp. 125-127 (1986)	LIPINSKI 000705-000707
PTX0026	Lipinski Second Expert Report 13				1986	*J. Med. Chem*., vol. 29, no. 8, pp. 1327-29 (1986)	LIPINSKI 000815-000817
PTX0027	Lipinski Second Expert Report 14				1997	*J. of Biol. Chem*., vol. 272, no. 36, pp. 22438-22446 (1997)	LIPINSKI 000631-000639
PTX0028	Lipinski Second Expert Report 15				1995	*Annual Review of Pharmacology and Toxicology*, vol. 35, pp. 277-305 (1995)	LIPINSKI 002683-002713
PTX0029	Lipinski Second Expert Report 16				1989	*J. Med. Chem*, vol. 32, pp. 1970-1977 (1989)	LIPINSKI 000748-000754
PTX0030	Lipinski Second Expert Report 17				1992	*J. of Med. Chem*., vol. 35, no. 6, pp.1049-1057, (1992)	LIPINSKI 000763-000771
PTX0031	Lipinski Second Expert Report 18				1985	*Biochemical and Biophysical Res. Commun*., vol. 128, no. 1, 477-484 (1985)	LIPINSKI 000877-000884
PTX0032	Lipinski Second Expert Report 19				1985	*The Journal of Biological Chemistry*, vol. 260, no. 8, pp. 4591-4597 (1985)	LIPINSKI 000755-000762
PTX0033	Lipinski Second Expert Report 20				2006	*Ch. 3, Analogue-based Drug Discovery*, pp. 115-136 (Fischer and Ganellin, eds., 2006)	LIPINSKI 000921-000944
PTX0034	Lipinski Second Expert Report 21				1986	*Drugs and People, Ch. 4: Molecular Modifications of Prototype Drugs*, pp. 38-42 (1986)	LIPINSKI 000687-000690
PTX0035	Lipinski Second Expert Report 22				1988	*Br. J. Clin. Pharmac*., vol. 25, pp. 387-396 (1988)	LIPINSKI 000867-000876
PTX0036	Lipinski Second Expert Report 23				12/9/1986	U.S. Patent 4,628,098	LIPINSKI 001160-001170
PTX0037	Lipinski Second Expert Report 24					Substructure search 4th position	LIPINSKI 001321-001330
PTX0038	Lipinski Second Expert Report 25					Search for drugs containing trifluorethoxy prior to 1985	LIPINSKI 001331-001352
PTX0039	Lipinski Second Expert Report 26				6/14/2007	Compounds Incorporating the Trifluoroethoxy Group with Pharmaceutical Activity-Compounds After 1985	LIPINSKI 001353-001389
PTX0040	Lipinski Second Expert Report 27				10/00/1990	Chem. Pharm. Bull., vol. 38(10), pp. 2853-2858 (1990)	LIPINSKI 000564-000573
PTX0041	Lipinski Second Expert Report 28				10/1/1981	Effects of a Substituted Benzimidazole (H 149/94) on Gastric Acid Secretion in Humans (from Gastroenterology)	LIPINSKI 000846-000851
PTX0042	Lipinski Second Expert Report 29				6/18/1973	"Aromatic" Substituent Constants for Structure-Activity Correlations (from Journal of Medicinal Chemistry)	LIPINSKI 000714-000719.004

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 18 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0043	Lipinski Second Expert Report 30				8/24/1983	*Drug Metabolism and Disposition* , vol. 12, no. 4, pp. 414-420 (1984)	LIPINSKI 000822-000828
PTX0044	Lipinski Second Expert Report 31				2006	Analogue-based Drug Discovery Chapter 2: Esomeprazole in the Framework of Proton-Pump Inhibitor Development	LIPINSKI 000782-000814
PTX0045	Lipinski Second Expert Report 32				7/11/2007	Translation of TAKEDA 436694-436709 (Research Report #10028)	LIPINSKI 001245-001271
PTX0046	Lipinski Second Expert Report 33				1999	Section of Proton Pump Inhibitors pp. 1-20 (Olbe, ed)	LIPINSKI 000972-000997
PTX0047	Lipinski Second Expert Report 34				1972	Dissociation Constants of Organic Bases In Acqueous Solution: Supplement 1972 (small selection)	LIPINSKI 000860-000866
PTX0048	Lipinski Second Expert Report 35				1999	Section of Proton Pump Inhibitors pp. 47-59 (Olbe ed)	LIPINSKI 000998-001017
PTX0049	Lipinski Second Expert Report 36				12/00/1974	Fluorinated compounds of medicinal interest *Chemtech pp. 752-757 (1974)*	LIPINSKI 000708-000713
PTX0050	Lipinski Second Expert Report 37				3/9/1977	Tetrahedron Report Number 31: Introduction of Fluorine into Organic Molecules: Why and How	LIPINSKI 000906-000920
PTX0051	Lipinski Second Expert Report 38				3/10/1981	U.S. Patent 4,255,431	LIPINSKI 002401-002414
PTX0052	Lipinski Second Expert Report 39				10/00/1987	Structure-activity relationships of omeprazole analogues and their mechanism of action	LIPINSKI 000818-000821
PTX0053	Lipinski Second Expert Report 40				2/00/2003	A Proton-Pump Inhibitor Expedition: The Case Histories of Omeprazole and Esomeprazole	LIPINSKI 000852-000859
PTX0054	Lipinski Second Expert Report 41				11/26/1985	U.S. Patent 4,555,518	LIPINSKI 002662-002677
PTX0055	Lipinski Second Expert Report 42				9/18/1984	U.S. Patent 4,472,409	LIPINSKI 002415-002424
PTX0056	Lipinski Second Expert Report 43				8/27/1982	Effect of substituted benzimidazoles on acid secretion in isolated and enriched guinea pig parietal cells Gut *Vol. 24:557-560*	LIPINSKI 000956-000959
PTX0057	Lipinski Second Expert Report 44				7/3/2007	Translation of TAKEDA 040730 (February 1982 Monthly Report)	LIPINSKI 001172-001173
PTX0058	Lipinski Second Expert Report 45					TAKEDA-050561-050773	LIPINSKI 001974-002186
PTX0059	Lipinski Second Expert Report 46					AG Screening Data -TAKEDA-050774-050987	LIPINSKI 002187-002400
PTX0060	Lipinski Second Expert Report 47					TAKEDA-050988-051237	LIPINSKI 001390-001639
PTX0061	Lipinski Second Expert Report 48				7/4/1986	Translation of TAKEDA 436710-436733 (Research Report No. 10031)	LIPINSKI 001272-001320
PTX0062	Lipinski Second Expert Report 49				10/00/1982	Translation of TAKEDA-040780 (October 1982 Monthly Report)	LIPINSKI 001174-001176

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 19 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0063	Lipinski Second Expert Report 50				6/00/1983	Translation of TAKEDA-040832-040833 (June 1983 Monthly Report)	LIPINSKI 001177-001181
PTX0064	Lipinski Second Expert Report 51				6/00/1983	Translation of TAKEDA-040834 (June 1983 Monthly Report)	LIPINSKI 001182-001184
PTX0065	Lipinski Second Expert Report 52				7/00/1983	Translation of TAKEDA-04083 (July, 1983 Monthly Report)	LIPINSKI 001185-001187
PTX0066	Lipinski Second Expert Report 53				8/00/1983	Translation of TAKEDA-040843 (August, 1983 Monthly Report)	LIPINSKI 001222-001224
PTX0067	Lipinski Second Expert Report 54				9/00/1983	Translation of TAKEDA-040859-040860 (September, 1983 Monthly Report)	LIPINSKI 001188-001192
PTX0068	Lipinski Second Expert Report 55				9/00/1983	Translation of TAKDEA-040861 (September, 1983 Monthly Report)	LIPINSKI 001225-001227
PTX0069	Lipinski Second Expert Report 56				10/5/1983	Translation of TAKEDA-040869 (October, 1983 Monthly Report)	LIPINSKI 001228-001230
PTX0070	Lipinski Second Expert Report 57				11/8/1983	Translation of TAKEDA-040875-040876 (November, 1983 Monthly Report)	LIPINSKI 001231-001235
PTX0071	Lipinski Second Expert Report 58				11/3/1983	Translation of TAKEDA-040877 (November, 1983 Monthly Report)	LIPINSKI 001236-001238
PTX0072	Lipinski Second Expert Report 59				12/5/1983	Translation of TAKEDA-040886 (December, 1983 Monthly Report)	LIPINSKI 001239-001241
PTX0073	Lipinski Second Expert Report 60				1/5/1984	Translation of TAKEDA-040893 (January, 1984 Monthly Report)	LIPINSKI 001193-001195
PTX0074	Lipinski Second Expert Report 61				2/3/1984	Translation of TAKEDA-040901 (February, 1984 Monthly Report)	LIPINSKI 001196-001198
PTX0075	Lipinski Second Expert Report 62				3/2/1984	Translation of TAKEDA-040909 (March, 1984 Monthly Report)	LIPINSKI 001199-001201
PTX0076	Lipinski Second Expert Report 63				5/3/1984	Translation of TAKEDA-040924 (May, 1984 Monthly Report)	LIPINSKI 001202-001204
PTX0077	Lipinski Second Expert Report 64				6/4/1984	Translation of TAKEDA-040931 (June, 1984 Monthly Report)	LIPINSKI 001205-001207
PTX0078	Lipinski Second Expert Report 65				7/5/1984	Translation of TAKEDA-040938 (July, 1984 Monthly Report)	LIPINSKI 001208-001210
PTX0079	Lipinski Second Expert Report 66				8/7/1984	Translation of TAKEDA-040944 (August, 1984 Monthly Report)	LIPINSKI 001211-001213
PTX0080	Lipinski Second Expert Report 67				8/6/1984	Translation of TAKEDA-040945 (August, 1984 Monthly Report)	LIPINSKI 001242-001244
PTX0081	Lipinski Second Expert Report 68				9/7/1984	Translation of TAKEDA-040951-040952 (September, 1984 Monthly Report)	LIPINSKI 001214-001218

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 20 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0082	Lipinski Second Expert Report 69				9/5/1984	Translation of TAKEDA-040953 (September, 1984 Monthly Report)	LIPINSKI 001219-001221
PTX0083	Lipinski Second Expert Report 70					TAKEDA-050355-050560	LIPINSKI 001768-001973
PTX0084	Lipinski Second Expert Report 71				1988	*Scand. J. Gastroenterol.*, vol. 23 (suppl. 146), pp. 34-39, (1988)	LIPINSKI 000742-000747
PTX0085	Lipinski Second Expert Report 72				1988	*Digestive Diseases and Sciences*, vol. 33, no. 5, pp. 619-624 (1988)	LIPINSKI 000720-000725
PTX0086	Lipinski Second Expert Report 73				1990	*Gastroenterology*, vol. 99, pp. 345-351 (1990)	LIPINSKI 000691-000697
PTX0087	Lipinski Second Expert Report 74				1985	*Scand. J. Gastroenterol.*, vol. 20 (suppl. 108), pp. 53-69 (1985)	LIPINSKI 000698-000704
PTX0088	Lipinski Second Expert Report 75				1986	Proceedings of the First Int'l Symposium on Omeprazole, pp. 31-38, AB Hässle (Borg et al. ed. 1986)	LIPINSKI 000623-000630
PTX0089	Lipinski Second Expert Report 76				1999	*Am. J. Health-Syst. Pharm.*, vol. 56(suppl. 4), pp. S11-S17 (1999)	LIPINSKI 000885-000892
PTX0090	Lipinski Second Expert Report 77				5/00/1990	*Comparative Stability Study for Lansoprazole and Omeprazole in Solid State*	LIPINSKI 002678-002682
PTX0091	Whittle First Expert Report 1					Whittle CV	WHITTLE 000001-000080
PTX0092	Whittle First Expert Report 2					U.S. Patent 4,628,098	WHITTLE 000416-000426
PTX0093	Whittle First Expert Report 3					File History of U.S. Patent 4,628,098	WHITTLE 000081-000222
PTX0094	Whittle First Expert Report 5				1959	*Gastroenterology*, vol. 36, pp. 45-56 (1959)	WHITTLE 000832-000843
PTX0095	Whittle First Expert Report 6				1992	*FASEB*, vol. 6, pp.825-31 (1992)	WHITTLE 000623-000629
PTX0096	Whittle First Expert Report 7				1988	Ch. 10, in *Principles and Practice of Gastroenterology and Hepatology*, Elsevier Science Publishing, pp. 128-137 (1988)	WHITTLE 001027-001038
PTX0097	Whittle First Expert Report 8				1988	*Drug Intelligence & Clinical Pharmacy*, vol. 22, pp. 452-60 (1988)	WHITTLE 000698-000706
PTX0098	Whittle First Expert Report 9				1991	*Annals Internal Med., vol. 114, p. 307-319 (1991)*	WHITTLE 000925-000937
PTX0099	Whittle First Expert Report 10				1980	*Brain Res. Bull., vol. 5, Suppl. 1, pp. 7-14 (1980)*	WHITTLE 000427-000434
PTX0100	Whittle First Expert Report 11				1976	*Eur. J. Pharmacology*, vol. 40, pp. 233-239 (1976)	WHITTLE 001052-001058
PTX0101	Whittle First Expert Report 12				1979	*Gastroenterology*, vol. 77, pp. 761-67 (1979)	WHITTLE 000857-000863
PTX0102	Whittle First Expert Report 13				1992	*Life Sci.*, vol. 51, pp. 1833-42 (1992)	WHITTLE 000577-000586
PTX0103	Whittle First Expert Report 14				1988	*Am. J. Physiol.*, vol. 18, pp. G395-402 (1988)	WHITTLE 000917-000924
PTX0104	Whittle First Expert Report 15				1989	*J. Pharmacology Experimental Therapeutics*, vol. 248 no. 2, pp. 806-815 (1989)	WHITTLE 000891-000900

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 21 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0105	Whittle First Expert Report 16					Search for citations to Satoh	WHITTLE 000447-000546
PTX0106	Whittle First Expert Report 17				2000	*Eur. J. Gastroent. & Hepatology*, vol. 12, pp. 313-318 (2000)	WHITTLE 000570-000576
PTX0107	Whittle First Expert Report 18				1984	*Pharmacological Res. Comm.*, vol. 16, no. 7, pp. 653-664 (1984)	WHITTLE 000977-000989
PTX0108	Whittle First Expert Report 19				1999	*Jpn. J. Pharmacol.*, Vol. 80, pp. 229-235, (1999)	WHITTLE 000844-000850
PTX0109	Whittle First Expert Report 20				1993	*Aliment. Pharmacol. Ther.*, vol. 7, pp. 237-246 (1993)	WHITTLE 000938-000947
PTX0110	Whittle First Expert Report 21				1991	*Chem. Pharm. Bull*, vol. 39(7), pp. 1828-1831 (1991)	WHITTLE 000707-000710
PTX0111	Whittle First Expert Report 22				1985	*Acta Physiologica Hungarica*, vol. 65(3), pp. 263-255 (1985)	WHITTLE 000603-000606
PTX0112	Whittle First Expert Report 23				1996	*Aliment, Pharmacol. Ther.*, vol. 10, pp. 339-345 (1996)	WHITTLE 000587-000593
PTX0113	Whittle First Expert Report 24				1995	*Aliment Pharmacol. Ther.*, vol. 9, pp. 167-172 (1995)	WHITTLE 000617-000622
PTX0114	Whittle First Expert Report 25				1995	*Gen. Pharmacology*, vol. 26(7): 1455 - 1459 (1995)	WHITTLE 000964-000968
PTX0115	Whittle First Expert Report 26				1994	*Agents Actions*, vol. 41, pp. C228-C230 (1994)	WHITTLE 000594-000596
PTX0116	Whittle First Expert Report 27				1994	*J. Pharmacology & Expt. Therapeutics*, vol. 271, pp. 695-702 (1994)	WHITTLE 000736-000743
PTX0117	Whittle First Expert Report 28				1993	*Gut*, vol. 34, pp. 156-160 (1993)	WHITTLE 000959-000963
PTX0118	Whittle First Expert Report 29				1992	*J. Pharmacology & Expt. Therapeutics*, vol. 263, pp. 951-55 (1992)	WHITTLE 000731-000735
PTX0119	Whittle First Expert Report 30				1993	*Scand. J. Gastroent.*, Vol. 28, pp. 89-94 (1993)	WHITTLE 000597-000602
PTX0120	Whittle First Expert Report 31				1991	*Am. J. Physiol.*, vol. 261, pp. G213-G219 (1991)	WHITTLE 000801-000807
PTX0121	Whittle First Expert Report 32				1996	*Gut*, vol. 39, pp. 363-368 (1996)	WHITTLE 000563-000569
PTX0122	Whittle First Expert Report 33				1981	*"Indomethacin Produced Gastric Antral ulcers in the Refed Rat" Gastroenterology*, vol. 81, pp. 719-25 (1981)	WHITTLE 000871-000877
PTX0123	Whittle First Expert Report 34				1981	*Gastroenterology*, vol. 80, pp. 94-98 (1981)	WHITTLE 000435-000439
PTX0124	Whittle First Expert Report 35				1988	*Prostaglandins*, vol. 35, No. 2, pp. 137, 145 (1988)	WHITTLE 000234-000240
PTX0125	Whittle First Expert Report 36				1985	*Eur. J. Pharmacology*, vol. 116, pp. 153-157 (1985)	WHITTLE 001046-001051
PTX0126	Whittle First Expert Report 37				1981	*Prostaglandins*, vol. 21, pp. 131-137 (Supp. 1981)	WHITTLE 000901-000907
PTX0127	Whittle First Expert Report 38				1999	*N. Engl. J. Med.*, vol. 340, no. 24, pp. 1888-99 (1999)	WHITTLE 001015-001026
PTX0128	Whittle First Expert Report 39				2003	*Fundamental & Clinical Pharmacology*, vol. 17, pp. 301-313 (2003)	WHITTLE 001059-001071
PTX0129	Whittle First Expert Report 40				1984	*Digestive Diseases and Sci.*, vol. 29, no.4, fig. 2 and pp. 330-335 (1984)	WHITTLE 001039-001045
PTX0130	Whittle First Expert Report 41					TAKEDA 649161	WHITTLE 000347
PTX0131	Whittle First Expert Report 42					TAKEDA 040942	WHITTLE 000248-000250

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 22 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0132	Whittle First Expert Report 43					TAKEDA 040950	WHITTLE 000251-000253
PTX0133	Whittle First Expert Report 44					TAKEDA 436710-436733	WHITTLE 000285-000333
PTX0134	Whittle First Expert Report 45					TAKEDA 040957	WHITTLE 000254-000256
PTX0135	Whittle First Expert Report 46					TAKEDA 040954-040956	WHITTLE 000440-000446
PTX0136	Whittle First Expert Report 47					Charts re: Inhibitions	WHITTLE 000547-000562
PTX0137	Whittle First Expert Report 48					Certified translation of TAKEDA 639116-117	WHITTLE 001852-001856
PTX0138	Whittle First Expert Report 49					Certified translation of TAKEDA 642665-670	WHITTLE 001857-001869
PTX0139	Whittle First Expert Report 50					Certified translation of TAKEDA 642701-706	WHITTLE 001883-001895
PTX0140	Whittle First Expert Report 51					Certified translation of TAKEDA 642707-711	WHITTLE 001896-001906
PTX0141	Whittle First Expert Report 52					Certified translation of TAKEDA 642777-781	WHITTLE 001916-001929
PTX0142	Whittle First Expert Report 53					Certified translation of TAKEDA 642785	WHITTLE 001927-001929
PTX0143	Whittle First Expert Report 54					Certified translation of TAKEDA 642773-776	WHITTLE 001907-001915
PTX0144	Whittle First Expert Report 55					Certified translation of TAKEDA 642786-789	WHITTLE 001930-001938
PTX0145	Whittle First Expert Report 56					Certified translation of TAKEDA 649114-122	WHITTLE 001956-001974
PTX0146	Whittle First Expert Report 57					Certified translation of TAKEDA 649106-113	WHITTLE 001939-001955
PTX0147	Whittle First Expert Report 58					Certified translation of TAKEDA 649123-128	WHITTLE 001975-001987
PTX0148	Whittle First Expert Report 59					Certified translation of TAKEDA 638780-784	WHITTLE 001819-001829
PTX0149	Whittle First Expert Report 60					Certified translation of TAKEDA 638807-814	WHITTLE 001830-001846
PTX0150	Whittle First Expert Report 61					Certified translation of TAKEDA 639114-115	WHITTLE 001847-001851
PTX0151	Whittle First Expert Report 62					Certified translation of TAKEDA 642671-676	WHITTLE 001870-001882
PTX0152	Whittle First Expert Report 63					Certified translation of TAKEDA 649135-140	WHITTLE 001988-002000
PTX0153	Whittle First Expert Report 64					TAKEDA 642700	WHITTLE 000223
PTX0154	Whittle First Expert Report 65					PSL 000050-000052	WHITTLE 001121-001123
PTX0155	Whittle First Expert Report 66					PSL 000587-000588	WHITTLE 001658-001659
PTX0156	Whittle First Expert Report 67					PSL 000592-000593	WHITTLE 001663-001664
PTX0157	Whittle First Expert Report 68					U.S. Patent 4,472,409	WHITTLE 000390-000399
PTX0158	Whittle First Expert Report 69					U.S. Patent 4,555,518	WHITTLE 000400-000415
PTX0159	Whittle First Expert Report 70					TAKEDA 100743	WHITTLE 000257
PTX0160	Kaunitz Expert Report 1					Kaunitz CV	
PTX0161	Fennerty Expert Report A					Fennerty CV	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 23 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0162	Fennerty Expert Report C				2006	Review article: fast acid control and rapid symptom relief for patients with gastro-oesophageal reflux disease- the evidence from proton pump inhibitor studies *Aliment Pharmacol Ther Symp. 2:327-339 (2006)*	
PTX0163	Fennerty Expert Report D				1996	Efficacy and safety in the treatment of erosive reflux esophagitis *Am J Gastro 91:1749-1757 (1996)*	
PTX0164	Fennerty Expert Report E				1997	Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion *Aliment Pharmacol Ther 11:359-364 (1997)*	
PTX0165	Fennerty Expert Report F				2005	What are the alternative approaches to the long-term management of GERD? *Aliment Pharmacol Ther 22:1-6 (2005)*	
PTX0166	Fennerty Expert Report G				1993	Lansoprazole versus omeprazole in short term treatment of reflux oesophagitis *Scand J Gastro 224-228*	
PTX0167	Fennerty Expert Report H				2001	Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies *Am J Gastro 96:1704-1710 (2001)*	
PTX0168	Fennerty Expert Report I				1999	pH, Healing rate, and symptom relief in patients with GERD *Yale J Bio Med 72:181-194*	
PTX0169	Fennerty Expert Report J				1998	Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia *Aliment Pharmacol Ther 13:413-419*	
PTX0170	Fennerty Expert Report K				2004	Systematic review: is there excessive use of proton pump inhibitors in gastro-esophageal reflux disease? *Aliment Pharmacol Ther 20:1241-1251 (2004)*	
PTX0171	Fennerty Expert Report L				2005	Pharmacokinetics of proton pump inhibitors in children *Clin Pharma 44:441-466 (2005)*	
PTX0172	Fennerty Expert Report M				2005	Early heartburn relief with proton pump inhibitors: A systematic review and meta-analysis of clinical trials *Clini Gastro Hepatology 3:553-563 (2005)*	
PTX0173	Fennerty Expert Report N				1997	Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole *Aliment Pharmacol Ther 10:757-763 (1996)*	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 24 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0174	Fennerty Expert Report O				2003	Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors *Aliment Pharmacol Ther 17:1507-1514 (2003)*	
PTX0175	Fennerty Expert Report P				1999	Safety profile of the proton pump inhibitors *Am J Health-Sys Pharm 56:S11-S17 (1999)*	
PTX0176	Fennerty Expert Report Q				2001	Comparing lansoprazole and omeprazole in onset of heartburn relief: Results of a randomized controlled trial in erosive esophagitis patients *Am J Gastro 96:3089-3098 (2001)*	
PTX0177	Fennerty Expert Report R				2003	Systematic review: direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic disease *Aliment Pharmacol Ther 18:559-568 (2003)*	
PTX0178	Fennerty Expert Report S					Med-psych drug-grug interactions update Gastrointestinal medications *Psychosomatics 48:79-85*	
PTX0179	Fennerty Expert Report T					Prilosec package insert	
PTX0180	Fennerty Expert Report U					Prevacid package insert	
PTX0181	Fennerty Expert Report V					Top 200 brand-name drugs by retail dollars in 2006	
PTX0182	Fennerty Expert Report W					Prevacid 1995-2006 Historical Units/Gross Sales/Net Sales	
PTX0183	Fennerty Expert Report X					Prevacid advertising produced at TAP 0273505-0273542; Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized controlled trial in erosive esophagitis patients produced at TAP 0273643-0273646 and TAP 0273566-0273669	
PTX0184	Dajani Expert Report A					Curriculum Vitae	
PTX0185	Dajani Expert Report D				12/9/1996	U.S. Patent 4,628,098	TVL 010937-010943
PTX0186	Dajani Expert Report E					Notebook pages produced at TAKEDA 642702-642706; 639114-639117; 425591-425602; 425605-425656; 441606-441613; 441648-441658	various TAKEDA production ranges
PTX0187	Dajani Expert Report F				9/00/1986	AG-1749 Research	TAKEDA 571236-571279
PTX0188	Dajani Expert Report G				6/26/2007	Study: Evaluation of Compounds A and B Inhibition of Indomethacin Induced Gastric Mucosal Lesions in Rats Amended Report	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 25 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0189	Dajani Expert Report I				12/00/1993	European Patent EP-B-174,726 Takeda Chemical Industries Co. And Opposition by AB Hassle Appeal Brief	
PTX0190	Dajani Expert Report J				9/18/1984	U.S. Patent 4,472,409	
PTX0191	Dajani Expert Report K				9/7/1984	Translations of Monthly Reports September 1984 through November 1984 showing production numbers of TAKEDA 040951-040957; 040965-040970; 040978-040985	
PTX0192	Dajani Expert Report L					Dong CV	
PTX0193	Dajani Expert Report M				11/29/2006	Mahadevan cover letter to Dong and Safety Data Sheet for O-5361	
PTX0194	Dajani Expert Report N				2007	I8280 Indomethacin information from sigmaalrich.com	
PTX0195	Solny Expert Report A				9/27/2005	Solny CV	
PTX0196	Solny Expert Report D				2001	Clinical Reviews: Lessons Learned from Intragastric pH Monitoring	TVL 063402-063408
PTX0197	Solny Expert Report E				7/00/2006	Drug Class Review on Proton Pump Inhibitors	TVL 063419-063514
PTX0198	Solny Expert Report F				9/00/2003	Management of Gastroesophageal Reflux Disease	TVL 063409-063418
PTX0199	Solny Expert Report G				1/00/2007	Consumer Reports Best Buy Drugs: Drugs to Treat Heartburn, Ulcers, and Stomach Acid Reflux: The Proton Pump Inhibitors-Comparing Effectiveness, Safety, and Price	TVL 063992-064005
PTX0200	Solny Expert Report H				2001	Comparing Lansoprazole and Omeprazole in Onset of Heartburn Relief: Results of a Randomized, Controlled Trial in Erosive Esophagitis Patients	TVL 063687-063696
PTX0201	Solny Expert Report I				2000	Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastgroesophageal reflux disease and stress-related erosive syndrome *Gastro 118:S9-S31 (2000)*	TVL 063350-063372
PTX0202	Sony Expert Report J				5/00/2002	Journal Club Table of Contents and blurb: Lansoprazole	TVL 063390-063391
PTX0203	Solny Expert Report K				1/30/2003	Symptom relief in patients with reflux espohagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole	TVL 064021-064027
PTX0204	Lenz Expert Report A					Lenz CV	
PTX0205	Lenz Expert Report D				12/9/1986	U.S. Patent 4,628,098 with certificates of correction and extension of patent term	TVL 008408-008416
PTX0206	Lenz Expert Report E				1980	The Pharmacological Basis of Therapeutics Chapter 42: Gastric Antacids and Digestants	TVL 063899-063914

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 26 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0207	Lenz Expert Report F				1980	The Pharmacological Basis of Therapeutics Chapter 7: Atropine, Scopolamine, and Related Antimuscarinic Drugs	TVL 063915-063934
PTX0208	Lenz Expert Report G				1980	The Pharmacological Basis of Therapeutics Chapter 26: Histamine and 5-Hydroxytryptamine (Serotonin) and Their Antagonists	TVL 063935-063943
PTX0209	Lenz Expert Report H				3/12/1981	Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase	TAKEDA 362159-362161
PTX0210	Lenz Expert Report I				3/10/1981	U.S. Patent 4,255,431	TVL 011020-011029
PTX0211	Lenz Expert Report J				1990	Omeprazole: The First Proton Pump Inhibitor	TAKEDA 360478-360531
PTX0212	Lenz Expert Report K				1984	The New England Journal of Medicine: Pump Blockers and Ulcer Disease New Engld. J. Med., vol. 310, no. 12, pp. 785-786 (1984)	TVL 063219-063221
PTX0213	Lenz Expert Report L				6/00/1984	Translation of Monthly Report June, 1984 showing production numbers of TAKEDA 040929-040935	
PTX0214	Lenz Expert Report M				7/00/1984	Translation of Monthly Report, July 1984 showing production numbers of TAKEDA 040936-040942	
PTX0215	Lenz Expert Report N				1985	Structure activity relationships of substituted benzimidazoles	TVL 059671-059679
PTX0216	Lenz Expert Report O				1985	Dissociation Constants of Organic Bases in Aqueous Solution pp. 1-4; 141-176 plus references and index	TVL 065643-065712
PTX0217	Lenz Expert Report P				1972	Dissociation Constants of Organic Bases in Aqueous Solution: Supplement 1972	TVL 065713-065839
PTX0218	Lenz Expert Report Q				1991	A Survey of Hammet Substituent Constants and Resonance and Field Parameters	TVL 063319-063349
PTX0219	Lenz Expert Report R				7/8/1954	Steric Effects in Displacement Reactions. III. The Base Strengths of Pyridine, 2,6-Lutidine and the Monoalkylpyridines	TVL 063303-063306
PTX0220	Lenz Expert Report S				1964	Structure and Reactivity in the Oyridine Series. Part I. Acid Dissociation Constants of Pyridinium Ions.	TVL 065625-065630
PTX0221	Lenz Expert Report T				9/18/1972	Thermodynamics of Protonation of Substituted Pyridines in Aqueous Solutions	TVL 063307-063311
PTX0222	Lenz Expert Report U				1984	Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H + K)-ATPhase within the parietal cell *Biochimico et Bio Acta 778: 549-558*	TVL 063980-063989
PTX0223	Lenz Expert Report V				9/18/1984	U.S. Patent 4,472,409	TVL 011030-011039

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 27 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0224	Lenz Expert Report W				11/26/1985	U.S. Patent 4,555,518	TVL 059822-059837
PTX0225	Lenz Expert Report X				1/00/1974	Fluorinated compounds of medicinal interest *Chemtech pp. 752-757 (1974)*	TVL 065998-066004
PTX0226	Lenz Expert Report Y				3/9/1977	Tetrahedron Report Number 31: Introduction of Fluorine into Organic Molecules: Why and How	TVL 062415-062429
PTX0227	Lenz Expert Report Z				3/19/1990	Synthesis of 2-[[(4-Fluoroalkoxy-2-pyridly)methyl]sulfinyl]-1H-benzimidazoles as Antiulcer Agents	TAKEDA 015682-015687
PTX0228	Lenz Expert Report AA				8/30/1977	U.S. Patent 4,045,563	TVL 010912-010925
PTX0229	Lenz Expert Report BB				8/30/1977	U.S. Patent 4,045,564	TVL 064006-064012
PTX0230	Lenz Expert Report CC				3/00/1965	Structure and Basicity. Part III. The Basicity of Homogeneously Substituted Cyclotriphosphazatrienes and Cyclotetraphosphazatetraenes	TVL 059748-059755
PTX0231	Lenz Expert Report DD					Molecule Comparison Chart	TAKEDA 050988; 051183-051184
PTX0232	Lenz Second Expert Report B				2005	Glaxo Wellcome: Knowledge Acquisition and Learning	TVL 069353-069355
PTX0233	Lenz Second Expert Report C				3/12/1981	Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase	TAKEDA 362159-362161
PTX0234	Lenz Second Expert Report D				1/00/1984	Effects of a Proton Pump Inhibitor, Omeprazole, on Gastric Secretion and Gastric and Duodenal Ulcers or Erosions in Rats (from Digestive Diseases and Sciences)	TVL 069356-069364
PTX0235	Lenz Second Expert Report E				10/00/1989	The Pharmacology of Antiulcer Drugs (from DICP, The Annals of Pharmacotherapy)	TVL 069365-069373
PTX0236	Lenz Second Expert Report F				2/00/1991	How do you manage the patient with persistent reflux oesophagitis? (from New Ethicals)	TAKEDA 683410-683412
PTX0237	Hirsch Expert Report A					Hirsch CV	
PTX0238	Hirsch Expert Report D					PSL Data chart	
PTX0239	Hirsch Expert Report E					Takeda Data chart	
PTX0240	Hirsch Expert Report F				1988	Applied regression analysis and other multivariable methods pp. 1, 60, 189-195; 319	
PTX0241	Hirsch Expert Report G				1990	Mathematical statistics with applications section 5.8 pp. 241-247	
PTX0242	Hirsch Expert Report H				1971	Probabilities of the type 1 errors of the Welch test for the Hehrens-Fischer problem *J Am Statistical Assoc 66: 605-608*	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 28 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0243	Hirsch Expert Report I				6/26/2007	PSL Study: Evaluation of Compounds A and B Inhibition of Indomethacin Induced *Gastric Mucosal Lesions in Rats Amended Report (20637)*	
PTX0244	Hirsch Expert Report J				6/26/2007	PSL Study: Effect of Compound C Against Indomethacin Induced Gastric Mucosal Lesions in Rats (21149)	
PTX0245	Hirsch Expert Report K				6/26/2007	PSL Study: Effect of Compound D Against Indomethacin Induced Gastric Mucosal Lesions in Rats (21411 & 21149)	
PTX0246	Hirsch Expert Report L					Notebook pages produced at TAKEDA 639117; 642666-642667; 642702-642706; 642780-642785; 642789; 649115-649116; 649123-649124; 638780-638781; 638808-638809; 639115; 642672-642673; 649135-649136	various TAKEDA production ranges
PTX0247	Dong 1					PSL study report	PSL 000001-000021
PTX0248	Dong 2					PSL study report for compound C	PSL 000022-000027
PTX0249	Dong 3					PSL study report for compound D	PSL 000028-000036
PTX0250	Dong 4					raw data gastric lesions document	PSL 000310-000333
PTX0251	Dong 5					Raw data gastric lesions	PSL 000335-000399
PTX0252	Dong 6				12/9/1986	U.S. Patent 4,628,098	PSL 000120-000126
PTX0253	Dong 7					*"Indomethacin Produced Gastric Antral ulcers in the Refed Rat" Gastroenterology*, vol. 81, pp. 719-25 (1981)	PSL 000112-000119
PTX0254	Dong 8					PSL Protocol Amendment Study: 20637	PSL 000059-000081
PTX0255	Dong 9					Protocol deviation	PSL 000082-000086
PTX0256	Dong 10					Explanation of details from study 20637, indomethacin induced gastric lesions	PSL 000050-000057
PTX0257	Dong 11					Body weight and dosing sheet, production number	PSL 000166-000171
PTX0258	Dong 13					A collection of documents from Organix Incorporated,	ORG 000001-000074
PTX0259	Dong 14					J Pharma and Exep Therap by Gao Dong and others	
PTX0260	Boulet 01				9/12/2006	PSL Study number 060914-(7-8)R/20637	PSL 000043-000049
PTX0261	Boulet 02				6/26/2007	Evaluation of Compounds A and B Inhibition of Indomethacin...study	PSL 000005-000021
PTX0262	Boulet 03				11/5/2006	Explanation of details from study 20637 Indomethacin Induced Gastric Lesions	PSL 000050—000057
PTX0263	Boulet 04				9/19/2006	PSL Study 20637 Body Weight and Dosing Sheets	PSL 000166—000171
PTX0264	Boulet 05				9/19/2006	Study No. 20637 Individual Animal Data Sheet	PSL 000172—000308

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 29 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0265	Boulet 06				9/19/2006	Study No. 20637 Raw Data Gastric Lesions	PSL 000310-000333
PTX0266	Boulet 07				9/20/2006	Study No. 20637 Raw Data Gastric Lesions	PSL 000335—000399
PTX0267	Boulet 08				9/26/2006	Protocol Deviation Indomethacin Induced Gastric Mucosal Irritation	PSL 000082—000086
PTX0268	Boulet 09				10/13/2006	Protocol Amendment Indomethacin Induced Gastric Mucosal Irritation	PSL 000059—000084
PTX0269	Boulet 10				12/13/2006	SOP Deviation Study No. 20637	PSL 000087—000089
PTX0270	Boulet 11					Study 20637 Indomethacin Induced Gastric Lesions Explanation of re-use of animal numbers	PSL 000058
PTX0271	Boulet 12				12/15/2006	Study 20637 Study Notes	PSL 000094—000095
PTX0272	Boulet 13				12/6/2006	Study No. 21149 Raw Data Gastric Lesions	PSL 000466—000561
PTX0273	Boulet 14				12/8/2006	Study No. 21149 Body Weight and Dosing Sheet	PSL 000443—000444
PTX0274	Boulet 15				1/24/2007	Study No. 21411 Raw Data Gastric Lesions	PSL 000606-000661
PTX0275	Boulet 16				1/24/2007	Study No. 21411 Body Weight and Dosing Sheet	PSL 000587—000588
PTX0276	Boulet 17				12/8/2006	Study No. 21149 Dosing, Feed and Obs	PSL 000445—000447
PTX0277	Boulet 18				12/7/2006	Study No. 21149 Dosing, Feed and Obs	PSL 000458—000460
PTX0278	Boulet 19				12/6/2006	Study No. 21149 Dosing, Feed and Obs	PSL 000454—000456
PTX0279	Boulet 20				12/7/2006	Study No. 21149 Body Weight and Dosing Sheet	PSL 000440—000441
PTX0280	Boulet 21				12/6/2006	Study No. 21149 Body Weight and Dosing Sheet	PSL 000438—000439
PTX0281	Boulet 22				1/25/2007	Study No. 21141 Boy Weight and Dosing Sheet	PSL 000593
PTX0282	Boulet 23				1/24/2007	Study No. 21141 Dosing Feed and Obs	PSL 000589—000591
PTX0283	Boulet 24				1/25/2007	Study No. 21141 Dosing Feed and Obs	PSL 000594—000596
PTX0284	Jacoby 02				5/5/1981	U.S. Patent 4,265,900	
PTX0285	Jacoby 03				7/16/1986	Antisecretory Activity of Human, Dog, and Rat Metabolites of Fenectimine	
PTX0286	Jacoby 05				12/16/2006—12/17/2006	Inhibition of Indomethacin Induced Antral Ulcers	PSL 000401—000411
PTX0287	Jacoby 06				12/6/2006—12/8/2006	Table 1: Effect of Compound C (0-5346) Against Indomethacin Induced Gastric Antal Lesions	PSL 000462- 000465
PTX0288	Jacoby 07				12/7/2006	Study No. 21149 Raw Data Gastric Lesions	PSL 000532—000537
PTX0289	Jacoby 08				12/8/2006	Study No. 21149 Raw Data Gastric Lesions	PSL 000538—000561
PTX0290	Whittle 2					Whittle CV	WHITTLE 000001-000080
PTX0291	Whittle 3					U.S. Patent 4,628,098	WHITTLE 000416-000426

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 30 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0292	Whittle 5					Pharmacological profile of AG-1749	WHITTLE 000067
PTX0293	Whittle 6					Certified translation of TAKEDA 040957 (September 1984 Monthly Report)	WHITTLE 000254-000256
PTX0294	Whittle 7					Graphs titled Inhibition of IMAU by AG-1749	WHITTLE 000547-000562
PTX0295	Whittle 8					Certified translation of TAKEDA 642701-642706	WHITTLE 001883-001895
PTX0296	Lipinski 1					U.S. Patent 4,255,431	LIPINSKI 02401-02414
PTX0297	Lipinski 4					TAKEDA 050988-051237	LIPINSKI 001390-001639
PTX0298	Lipinski 5					Certified translation of TAKEDA 436710-436733	LIPINSKI 001272-001320
PTX0299	Lipinski 6				9/18/1984	U.S. Patent 4,472,409	LIPINSKI 002415-002424
PTX0300	Lipinski 7					U.S. Patent 4,555,518	LIPINSKI 002662-02677
PTX0301	Solny 4				2003	Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole and rabeprazole *J Gastro Hep 18:1392-1398*	TVL 064021-064027
PTX0302	Solny 5				1997	Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion *Aliment Pharmacol Ther 11:359-364 (1997)*	
PTX0303	Solny 7					Prilosec package insert	
PTX0304	Solny 8					Prevacid package insert	
PTX0305	Solny 9				2001	Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized controlled trial in erosive esophagitis patients *Am J Gastro 96:3089-3098 (2001)*	TVL 063687-063696
PTX0306	Solny 10				1993	Lansoprazole versus omeprazole in short term treatment of reflux oesophagitis *Scand J Gastro 224-228*	
PTX0307	Solny 11				1996	Efficacy and safety in the treatment of erosive reflux esophagitis *Am J Gastro 91:1749-1757 (1996)*	
PTX0308	Solny 12				1999	Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia *Aliment Pharmacol Ther 13:413-419 (1999)*	
PTX0309	Solny 13				1996	Rapid system relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole *Aliment Pharmacol Ther 10:757-763 (1996)*	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 31 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0310	Solny 14				2000	Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastgroesophageal reflux disease and stress-related erosive syndrome *Gastro 118:S9-S31 (2000)*	TVL 063350-063372
PTX0311	Solny 15				2007	Consumer Reports Best Buy Drugs	TVL 063992-064005
PTX0312	Solny 16				2007	Gastroesophageal reflux disease Best practice & research *Clinical Gastro 21:609-631 (2007)*	
PTX0313	Hirsch 1					*Biostatistical Analysis, 2nd Edition*	
PTX0314	Hirsch 3					*Statistical First Aid Interpretation of Health Research Data,* Chapter 7	
PTX0315	Hirsch 4					Table: Effect of Compound C (0-5346) Against Indomethacin Induced Gastric Antral Lesions	PSL 000462- 000465
PTX0316	Hirsch 6				1990	*Annals of Emergency Medicine,* 19:12 December 1990, p.1462-1468	
PTX0317	Hirsch 7				1988	*Applied Regression Analysis and Other Multivariable Methods, Ch. 5 (42-79); Ch. 6 (80-95)*	
PTX0318	Hirsch 8				2003	*Critical Care, Vol. 7, No. 6 (451-459)*	
PTX0319	Hirsch 9				1999	*Analyzing Data with GraphPad Prism*	
PTX0320	Hirsch 10				1992	*Statistical First Aid Interpretation of Health Research Data, Ch. 3*	
PTX0321	Hirsch 12				1979	*International Journal for Parasitology, Vol. 9, pp 395-399*	
PTX0322	Hirsch 13				1996	*Studying a Study and Testing a Test How to Read the Health Science Literature, Ch. 5*	
PTX0323	Hirsch 14				2004	*Pharmaceutical Statistics, 2004; 3: 217-222*	
PTX0324	Hirsch 16					PSL Protocol Deviation - Indomethacin Induced Gastric Mucosal Irritation	PSL 000082-000089
PTX0325	Lenz 01				2/28/2007	Affidavit of Direct Testimony of Professor Anton J. Hopfinger	
PTX0326	Lenz 02				2/19/1985	US Patent No. 4,500,708	
PTX0327	Lenz 03				6/12/1905	Omeprazole: The First Proton Pump Inhibitor	TAKEDA 360478-360531
PTX0328	Lenz 05				12/17/1990	A Study of Hammet Substituent Constants and Resonance and Field Parameters	TVL 063319-063349
PTX0329	Lenz 06				3/22/1984	Pump Blockers and Ulcer Disease	
PTX0330	Lenz 07				11/26/1985	U.S. Patent 4,555,518	TVL 059822-059837
PTX0331	Lenz 08				9/18/1984	U.S. Patent 4,472,409	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 32 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0332	Lenz 09				3/10/1981	U.S. Patent 4,255,431	TVL 011020-011029
PTX0333	Lenz 11				10/1/2005	Medicinal Chemical Properties of Successful Central Nervous System Drugs	
PTX0334	Lenz 12				8/29/2007	ChemSpider Beta Search on Pantoprazole	
PTX0335	Lenz 13				8/29/2007	ChemSpider Beta Search on Lansoprazole	
PTX0336	Lenz 14				8/29/2007	ChemSpider Beta Search on Raberprazole	
PTX0337	Lenz 15				8/29/2007	ChemSpider Beta Search on Omeprazole	
PTX0338	Lenz 16				12/9/1986	U.S. Patent 4,628,098 with certificates of correction and extension of patent term	TAKEDA 422685-422695
PTX0339	Lenz 18				6/7/2007	Patent Trademark and Copyright Laws-June 2007 Edition	
PTX0340	Chambliss Expert Report A					Chambliss CV	
PTX0341	Chambliss Expert Report D				9/3/1991	U.S. Patent 5,045,321	TVL 010962-010972
PTX0342	Chambliss Expert Report E				1985	Development of an oral formation of omeprazole Gastro Scand J Gastroenterol 1985; 20(suppl 108): 113-120	TVL 059548-059557
PTX0343	Chambliss Expert Report F				1985	Omeprazole: A Study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage *Gastro 88:64-69 (1985)*	TVL 065992-065997
PTX0344	Chambliss Expert Report G				1976	Kinetic analysis of penicillin degration in acidic media *J Pharma Sci 65: 1165-1170 (1976)*	TVL 065978-065984
PTX0345	Chambliss Expert Report H				1980	Digoxin degradation in acidic dissolution medium *J Pharma Sci 69: 410-413 (1980)*	TVL 063845-063848
PTX0346	Chambliss Expert Report I				1983	The forgotten dosage form: enteric-coated tablets *Pharma Tech*	TVL 065972-065977
PTX0347	Chambliss Expert Report J				1976	The theory and practice of industrial pharmacy pp. 36-37	TVL 065988-065991
PTX0348	Chambliss Expert Report K				1979	Chemical Stability of Pharmaceuticals Chapter 1 pp. 3-6	TVL 063880-063885
PTX0349	Chambliss Expert Report L				1975	Pharmaceutical Sciences pp. 1423-1424	TVL 063886-063888
PTX0350	Chambliss Expert Report M				1989	Pharmaceutical Pelletization Technology p. 226	TVL 063839-063841
PTX0351	Chambliss Expert Report N				1984	Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H + K)-ATPhase within the parietal cell *Biochimico et Bio Acta 778: 549-558*	TVL 063980-063989
PTX0352	Chambliss Expert Report O				12/9/1986	U.S. Patent 4,628,098 (no certificates)	TVL 010937-010943
PTX0353	Chambliss Expert Report P				8/11/1987	U.S. Patent 4,686,230	TVL 011082-011106
PTX0354	Chambliss Expert Report Q				3/10/1981	U.S. Patent 4,255,431	TVL 011020-011029

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 33 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0355	Chambliss Expert Report R				1/31/1985	Japanese patent filing number S58-125593	TVL 681580-681598
PTX0356	Chambliss Expert Report S				12/1/1998	British Pharmacopiea definition of Hydrotalcite pp. 694-695	
PTX0357	Chambliss Second Expert Report A					U.S. Patent 5,045,321	TVL 010962-010972
PTX0358	Chambliss Second Expert Report D				7/15/2004	Section XI.2 Manufacturing and Processing Instructions: Commercial Batch Records	TVL 006849-006907
PTX0359	Chambliss Second Expert Report E				1976	The Theory and Practice of Industrial Pharmacy pp. 373-374	TVL 069279-069282
PTX0360	Chambliss Expert Report F				1986	The Theory and Practice of Industrial Pharmacy p. 368	TVL 069283-069285
PTX0361	Chambliss Second Expert Report G					TAKEDA-739684 (page from file history)	TAKEDA 739684
PTX0362	Chambliss Second Expert Report H					Handbook of Pharmaceutical Excipients, Fifth Edition-Section on Magnesium Aluminum Silicate	TVL 069301-069307
PTX0363	Chambliss Second Expert Report I				7/4/1961	U.S. Patent 2,991,226	TVL 069286-069291
PTX0364	Chambliss Second Expert Report J				1975	Remington's Pharmaceutical Sciences pp. 1569-1570	TVL 063869-063871
PTX0365	Chambliss Second Expert Report K				1996	Modern Pharmaceutics (Third edition) pp. 359-361	TVL 069292-069296
PTX0366	Chambliss Second Expert Report L				1989	Pharmaceutical Pelletization Technology Chapter 1: Pellets: A General Overview	TVL 069308-069310
PTX0367	Chambliss Second Expert Report M					Particle Size Conversion Chart from sigmaalrich.com	
PTX0368	Chambliss Second Expert Report N				1976	The Theory and Practice of Industrial Pharmacy pp. 499-500	TVL 069297-069300
PTX0369	Chambliss Second Expert Report O				1/1/1985	The United States Pharmacopeia, Twenty-First Revision, pp. 1276-1279	TVL 059558-059564
PTX0370	Chambliss Rebuttal Report C				9/3/1991	U.S. Patent 5,045,321	TVL 010962-010972
PTX0371	Chambliss Rebuttal Report D				11/2/1988	Declaration of Shinichiro Hirai submitted for the '321 Patent	TAKEDA 739677-739680
PTX0372	Chambliss Rebuttal Report E				3/3/1992	U.S. Patent 5,093,132	TVL 010973-010986
PTX0373	Chambliss Rebuttal Report F				1986	The Theory and Practice of Industrial Pharmacy Chapter 8: Preformulation pp 171, 193-194	
PTX0374	Chambliss Rebuttal Report G				1986	Chemical Stability of Pharmaceuticals Chapter 6: Solid-State Chemical Decomposition pp.115-283	AMIDON 000237-000269
PTX0375	Chambliss Rebuttal Report H				1985	*Development of an oral formation of omeprazole Gastro Scand J Gastroenterol 1985; 20(suppl 108): 113-120*	TVL 059548-059557
PTX0376	Hirt Expert Report A				8/2/2007	Hirt letter to North Report #MRL3862 "Analytical Study of Lansoprazole Granules using Diamond Knife Microtomy, Time-of-Flight Secondary Ion Mass Spectroscopy, Laser Raman Spectroscopy, Scanning Electron Microscopy and Energy-Dispersive X-ray Spectroscopy"	HIRT 001-007

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 34 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0377	Hirt Expert Report A1					Attachment 1: ToFSIMS Spectra and Maps	HIRT 008-027
PTX0378	Hirt Expert Report A2					Attachment 2: Laser Raman Spectra and Images	HIRT 028-036
PTX0379	Hirt Expert Report A3					Attachment 3: SEM and EDS Spectra and Images	HIRT 037-042
PTX0380	Hirt Expert Report A4					Attachment 4: Chain of Custody Documents	HIRT 043-044
PTX0381	Hirt Expert Report A5					Attachment 5: Principal X-Ray Emission Energies	HIRT 045
PTX0382	Hirt Expert Report A6					Attachment 6: Materials Research Laboratories, Inc.	HIRT 046
PTX0383	Hirt Expert Report A7					Policy Statement	HIRT 047
PTX0384	Hirt Expert Report B					Hirt CV	
PTX0385	Bugay Expert Report 1					Bugay CV	BUGAY 00001-0013
PTX0386	Bugay Expert Report 2					Photographs of Lansoprazole bottles	BUGAY 0014
PTX0387	Bugay Expert Report 3					Photographs of individual components	BUGAY 0015
PTX0388	Bugay Expert Report 4					Photograph of Raman spectrometer	BUGAY 0016
PTX0389	Bugay Expert Report 5					Photograph of EDX Spectroscopy	BUGAY 0017
PTX0390	Bugay Expert Report 6					Raman spectrum for lansoprazole API	BUGAY 0018
PTX0391	Bugay Expert Report 7					Raman spectrum for magnesium carbonate	BUGAY 0019
PTX0392	Bugay Expert Report 8					Raman spectrum for titanium dioxide	BUGAY 0020
PTX0393	Bugay Expert Report 9					Raman spectrum for hypromellose	BUGAY 0021
PTX0394	Bugay Expert Report 10					Raman spectrum for talc	BUGAY 0022
PTX0395	Bugay Expert Report 11					Raman spectrum for sugar	BUGAY 0023
PTX0396	Bugay Expert Report 12					Spectrum overlay for components	BUGAY 0024
PTX0397	Bugay Expert Report 13					Spectrum overlay with absolute intensity scale	BUGAY 0025
PTX0398	Bugay Expert Report 14					Optical image of a granule surface	BUGAY 0026
PTX0399	Bugay Expert Report 15					Optical image of lansoprazole granule prepared for Raman spectroscopic mapping	BUGAY 0027
PTX0400	Bugay Expert Report 16					Raman map 222145-1 (Granule #4, six o'clock)	BUGAY 0028
PTX0401	Bugay Expert Report 17					Overlay	BUGAY 0029
PTX0402	Bugay Expert Report 18					Correlation chart	BUGAY 0030-0033
PTX0403	Bugay Expert Report 19					Position 3 from Granule #4	BUGAY 0034
PTX0404	Bugay Expert Report 20					Difference goodness of fit	BUGAY 0035
PTX0405	Bugay Expert Report 21					Representation of detectable lansoprazole (spatial position)	BUGAY 0036
PTX0406	Bugay Expert Report 22					Laboratory Notebook 2726	BUGAY 0037-0055
PTX0407	Bugay Expert Report 23					Graph	BUGAY 0056
PTX0408	Bugay Expert Report 24					Comparison charts	BUGAY 0057

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 35 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0409	Bugay Expert Report 25					Raman map 221131-6	BUGAY 0058
PTX0410	Bugay Expert Report 26					Optical image of granule	BUGAY 0059
PTX0411	Bugay Expert Report 27					Graph for lansoprazole in Raman map 221131-6	BUGAY 0060
PTX0412	Bugay Expert Report 28					Graph for magnesium carbonate in Raman map 221131-6	BUGAY 0061
PTX0413	Bugay Expert Report 29					Raman map 221131-6 (Granule #1, twelve o'clock position)	BUGAY 0062
PTX0414	Bugay Expert Report 30					Remaining 13 Raman maps	BUGAY 0063-0075
PTX0415	Bugay Expert Report 31					SEM image for reach granule	BUGAY 0076
PTX0416	Bugay Expert Report 32					Color coded EDX maps and composite maps	BUGAY 0077-0085
PTX0417	Bugay Expert Report 33					Color coded EDX maps and composite maps	BUGAY 0086-0087
PTX0418	Bugay Expert Report 34					Color coded EDX maps and composite maps	BUGAY 0088-0089
PTX0419	Bugay Expert Report 35					Fluorine map	BUGAY 0090
PTX0420	Bugay Expert Report 36					Optical image of magnesium outside the lansoprazole	BUGAY 0091
PTX0421	Bugay Expert Report 37					Optical image of magnesium in the intermediate layer	BUGAY 0092
PTX0422	Bugay Expert Report 38					EDX map	BUGAY 0093
PTX0423	Bugay Expert Report 39					Overlay of lansoprazole EDX with magnesium	BUGAY 0094
PTX0424	Bugay Expert Report 40					Expanded view of overlay of lansoprazole EDX with magnesium	BUGAY 0095
PTX0425	Bugay Expert Report 41				2007	Raman Analysis of Pharmaceutical in Applications of Vibrational Spectroscopyinf Pharmaceutical Research and Development	BUGAY 0096-0123
PTX0426	Bugay Expert Report 42				1999	Confocal Raman-Spectroscopy: Analytical Approach to Solid Dispersions and Mapping of *Drugs Pharm Res 16:1109-1113*	BUGAY 0124-0128
PTX0427	Bugay Expert Report 43				2005	Raman and EDXRF Chemical Imaging for Formulation process Development and Quality Control Spectroscopy	BUGAY 0129-0130
PTX0428	Bugay Expert Report 44					Teva ANDA ingredient list produced at TVL 006617	BUGAY 0131
PTX0429	Bugay Supplemental Expert Report 46					Granule # 4 file # 227996-4a and table	BUGAY 0133-0136
PTX0430	Bugay Supplemental Expert Report 47					Experimental Data Acquisition Parameters for Individual Materials	BUGAY 0137-0147
PTX0431	Bugay Supplemental Expert Report 48					Experimental Data Acquisition Parameters for 15-mg Granules	BUGAY 0148-0149
PTX0432	Bugay Supplemental Expert Report 49					Three spectral lines	BUGAY 0150
PTX0433	Bugay Supplemental Expert Report 50					Spatial position charts	BUGAY 0151-0159
PTX0434	Bugay Supplemental Expert Report 51					SEM and EDX Filenames	BUGAY 0160

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 36 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0435	Bugay Supplemental Expert Report 52					Composite map	BUGAY 0161
PTX0436	Bugay Supplemental Expert Report 53					Fluorine and magnesium images	BUGAY 0162-0163
PTX0437	Bugay Supplemental Expert Report 54					EDX map and overlay of lansoprazole EDX with magnesium	BUGAY 0164-0165
PTX0438	Bugay Supplemental Expert Report 55					Laboratory notebook 2726 for EDX and Raman analysis	BUGAY 0166-0194
PTX0439	Amidon Expert Report 1					Amidon CV	AMIDON 000001-000100
PTX0440	Amidon Expert Report 2				5/31/2007	In re Omeprazole Patent Litigation 2007 WL 1576153	AMIDON 000010-000225
PTX0441	Amidon Expert Report 3					Stabilization of a new antiulcer drug (lansoprazole) in the solid dosage forms Drug Dev and Indus Pharma produced at TAP 0194278-0194288	AMIDON 000226-000236
PTX0442	Amidon Expert Report 4				1986	Chemical Stability of Pharmaceuticals Chapter 6 Solid State Chemical Decomposition pp.115-283	AMIDON 000237-000269
PTX0443	Amidon Expert Report 5				1986	Handbook of Pharmaceutical Excipients Table of Contents and Index	AMIDON 000270-000280
PTX0444	Byrn Expert Report 1					Byrn CV	BYRN 0001-031
PTX0445	Byrn Expert Report 2					Sections from Teva ANDA produced at TVL 6613-6624; 6835-6847; 6850-6904; 6971-6972; 6974-7034; 7098-7100; 7711; 7537-7546	BRYN 0032-00191
PTX0446	Byrn Expert Report 3					Lansoprazole DR 30 mg Capsules Batch Summary produced at TVL 035179 (and other documents)	BYRN 0192-0242
PTX0447	Byrn Expert Report 4					Excerpts from Simona DiCapua deposition, pp. 1-8, 65-80, 105-116	BYRN 0243-0251
PTX0448	Byrn Expert Report 5					Raman and EDXRF Chemical Imaging for Formulation process Development and Quality Control Spectroscopy	BYRN 0252-0253
PTX0449	Byrn Expert Report 6					Various optical images cited in BUGAY report	BRYN 0254-0258
PTX0450	Byrn Expert Report 7					Various optical images cited in BUGAY report	BYRN 0259-0269
PTX0451	Byrn Expert Report 8				1990	Drugpexcipient incompatibility studies of the depeptide angiotensin-converting enzyme inhibitor, Moexipril hydrochloride: dry powder vs wet granulation *Pharma Res 7:379-383*	BYRN 0270-0274
PTX0452	Byrn Expert Report 9				2001	Effect of salf form on chemical stability of an ester prodrug of a glycoprotein Iib/IIIa receptor antagonist in solid dosage forms *International J of Pharma 223:81-87*	BRYN 0275-0281
PTX0453	Byrn Expert Report 10					Prevacid package insert	BYRN 0282-0317

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 37 of 38

EXHIBIT NUMBER	SOURCE	OFFERED	ADMITTED	WITNESS	DOC DATE	DESCRIPTION	PRODUCTION RANGE
PTX0454	Byrn Expert Report 11				1992	Stabilization of a new antiulcer drug (lansoprazole) in the solid dosage forms Drug Dev and Indus Pharma produced at TAP 0194278-0194288	BYRN 0318-0328
PTX0455	Byrn Supplemental Expert Report 12					Section XII In-Process Controls of Teva's ANDA produced at TVL 007110-007388	BRYN 0329-0607
PTX0456	Byrn Supplemental Expert Report 13					Section VI.3 Dissolution of Teva's ANDA produced at TVL 0239-246 and Section VI.7 Fasted Study produced at TVL 304-307 and Section VI.8 Postprandial Study produced at TVL 2794-2797 and Section VI.9 Sprinkle Study produced at TVL 04916-4918	BYRN 0608-0626
PTX0457	Byrn Declaration submitted with Claim Construction Exhibit E					Chemical Dictionary definition of	
PTX0458	Byrn Declaration submitted with Claim Construction Exhibit F					Dictionary of Chemistry definitions of	
PTX0459	Byrn Declaration submitted with Claim Construction Exhibit G					New International Dictionary definitions of	
PTX0460	Byrn Declaration submitted with Claim Construction Exhibit H				1990	Drugpexcipient incompatibility studies of the depeptide angiotensin-converting enzyme inhibitor, Moexipril hydrochloride: dry powder vs wet granulation *Pharma Res 7:379-383*	BYRN 0270-0274
PTX0461	Byrn Declaration submitted with Claim Construction Exhibit I					Solid-Sate Chemistry of Drugs Chapt 7 pp. 219-227	
PTX0462	Meyer Expert Report A				9/3/1991	U.S. Patent 5,045,321	TVL 010962-010972
PTX0463	Meyer Expert Report B					Meyer CV	
PTX0464	Meyer Expert Report E				11/00/2005	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline; Validation of Analytical Procedures: Text and Methodology Q2(R1)	
PTX0465	Meyer Expert Report F				2001	Infrared and Raman Characteristic Group Frequencies Tables and Charts (various non-consecutive pages)	
PTX0466	Vandaele Expert Report 1					Vandaele CV	
PTX0467	Vandaele Expert Report 3					Prevacid Annual Sales Revenue for 1995-2006 prepared by LECG, LLC	

Case 1:06-cv-00033-SLR Document 146-2 Filed 10/08/2007 Page 38 of 38